Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Edwards Lifesciences (NYSE:EW) had its price objective upped by equities researchers at Royal Bank Of Canada from $89.00 to $95.00 in a report issued on Friday, Marketbeat reports. The firm presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 15.18% from the company’s previous close.

EW has been the topic of several other research reports. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Finally, Barclays reissued an “overweight” rating and issued a $99.00 price objective (up previously from $95.00) on shares of Edwards Lifesciences in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $91.00.

Edwards Lifesciences Stock Performance

NYSE EW opened at $82.48 on Friday. The firm’s fifty day moving average price is $77.58 and its two-hundred day moving average price is $76.93. The stock has a market cap of $48.42 billion, a PE ratio of 11.87, a PEG ratio of 3.97 and a beta of 1.05. Edwards Lifesciences has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the first quarter valued at about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter valued at about $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $28,000. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences during the first quarter valued at about $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.